Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full-year 2024 financial results.

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced that it has entered ...

Teva, a global pharmaceutical leader, to install the SaverOne System across its entire fleet of 50 delivery trucks in IsraelPetah Tikvah, Israel, ...

1 Day TEVA -5.67% DJIA -0.28% S&P 500 -0.76% Health Care/Life Sciences 0.29% ...

Teva Pharmaceuticals International GmbH ... excluding Italy, and in Israel. This collaboration combines Teva’s deep commercial experience in biosimilars and its extensive distribution network ...

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit ...

On January 10, 2025, Teva Pharmaceutical Industries Ltd. and Samsung ... Formycon’s aflibercept biosimilar, in Israel and most of Europe. This agreement expands Teva’s partnership with ...

Teva Pharmaceutical (NYSE ... Formycon's biosimilar candidate to Eylea in Europe and in Israel, the company said Monday. This partnership combines Teva’s (TEVA) commercial experience in ...